research
Articles tagged with “research”
Stanford Study: Drug Combo Extends Ketamine Anti-Suicide Effects
Stanford researchers report first drug combination to extend ketamine's rapid anti-suicide effects, potentially changing treatment protocols.
FDA Clears MIND1 Trial: NRX-101 Plus Robotic TMS for Suicidality
The FDA has cleared the MIND1 trial testing NRX-101 plus robotic TMS for suicidality in treatment-resistant depression. What it means for ketamine patients.
Trump EO on Psychedelics: What It Means for Ketamine
President Trump's April 2026 executive order accelerating psychedelic research may reshape ketamine's regulatory and clinical landscape. Here's what we know.
Glutamate Pathway Treatments Reshape TRD Care in 2026
A 2026 review in Psychiatric Times highlights how esketamine and glutamate-targeting drugs are changing treatment-resistant depression care.
Ketamine and Immune Function: Immunomodulatory Effects of Low-Dose Ketamine
A research-focused review of ketamine's effects on the immune system, including its impact on innate and adaptive immunity, inflammatory cytokines, immune cell function, and implications for patients with autoimmune conditions and chronic inflammation.
Ketamine and the Gut-Brain Axis: How the Microbiome Influences Treatment Response
An in-depth look at the emerging research connecting ketamine therapy to the gut-brain axis, including how gut microbiome composition may predict and modulate ketamine's antidepressant and analgesic effects.
Low-Dose Ketamine Case Studies: Clinical Outcomes and Lessons
What do published low-dose ketamine case studies show? Review of clinical outcomes, dosing patterns, and lessons across depression, pain, and anxiety cases.
How to Start a Ketamine Therapy Practice: A Clinician's Guide
A comprehensive guide for clinicians on launching a ketamine therapy practice, covering DEA licensing, state regulations, clinical protocols, compounding pharmacy partnerships, liability considerations, and insurance frameworks.
Research and Clinical Evidence
Questions and answers about the scientific evidence supporting ketamine therapy, FDA approval status, landmark clinical trials, and the direction of ongoing research.
The Complete Guide to Low-Dose Ketamine Therapy
A comprehensive, evidence-based guide covering what low-dose ketamine is, how it works, all routes of administration, what patients can expect during treatment, efficacy data across conditions, safety considerations, and how to find qualified providers.
What Is the Response Rate for Ketamine Therapy?
Approximately 50 to 70 percent of patients with treatment-resistant depression respond to a course of low-dose ketamine infusions.
Biomarkers for Predicting Ketamine Treatment Response
A review of emerging biological markers that may predict which patients will respond to ketamine therapy, including inflammatory markers, neuroimaging signatures, genetic polymorphisms, and electrophysiological features.
Ketamine and Neuroinflammation: How Anti-Inflammatory Effects Support Mental Health
An evidence-based review of ketamine's anti-inflammatory mechanisms, including cytokine modulation, microglial regulation, and blood-brain barrier effects, and how these properties contribute to its antidepressant efficacy.
Sex Differences in Ketamine Treatment Response: Hormonal and Genetic Factors
Examining sex differences in ketamine treatment response, covering estrogen-NMDA interactions, progesterone modulation, genetic factors, and implications for personalized dosing.
Glutamate System Modulation by Low-Dose Ketamine
A comprehensive analysis of how low-dose ketamine modulates the glutamate system, including NMDA receptor antagonism, AMPA receptor potentiation, and the glutamate surge hypothesis. Reviews the excitatory-inhibitory balance framework and its therapeutic implications.
Ketamine Effects on Sleep Architecture: Slow-Wave Sleep and REM Changes
How does low-dose ketamine affect sleep? Review of slow-wave sleep enhancement, REM modulation, and links between sleep architecture and antidepressant action.
Telehealth Ketamine Marketing Compliance: Regulatory and Ethical Guidelines
What rules govern telehealth ketamine advertising? Review of FDA, FTC, and state guidance on marketing low-dose ketamine therapy through virtual platforms.
Anti-Inflammatory Properties of Low-Dose Ketamine: Cytokine Modulation
Review of the anti-inflammatory properties of low-dose ketamine, examining cytokine modulation, NF-kappaB signaling, microglial inhibition, and implications for depression and pain.
BDNF Signaling and Ketamine's Antidepressant Action
A detailed examination of how ketamine activates brain-derived neurotrophic factor signaling, TrkB receptor pathways, and the mTOR cascade to produce rapid antidepressant effects. Covers molecular mechanisms, clinical evidence, and implications for personalized treatment.
Neuroplasticity Mechanisms in Ketamine Therapy
An in-depth exploration of how low-dose ketamine promotes neural rewiring, synaptogenesis, and dendritic spine formation. This article examines the molecular and cellular pathways through which ketamine restores synaptic connectivity in mood and pain disorders.
Ketamine-Opioid System Interactions: Naltrexone Studies and Debate
Analysis of ketamine-opioid system interactions, examining the naltrexone blockade controversy, mu-receptor involvement in antidepressant effects, and implications for clinical practice.
Ketamine and the Default Mode Network: Neuroimaging Evidence
What does ketamine do to the default mode network? A review of fMRI connectivity studies, DMN changes in depression, and what the imaging evidence shows.
Rapid-Onset Antidepressant Mechanisms of Low-Dose Ketamine
An in-depth examination of why and how low-dose ketamine produces antidepressant effects within hours rather than weeks. This article reviews the glutamatergic hypothesis, the role of spontaneous NMDA receptor activity, and emerging theories that distinguish ketamine from conventional antidepressants.
Ketamine, Neuroplasticity, and Brain-Derived Neurotrophic Factor
How does low-dose ketamine drive neuroplasticity? Review of BDNF, mTOR pathway activation, synaptogenesis, and links to rapid antidepressant effects.
Low-Dose Ketamine for Acute Suicidal Ideation: Clinical Evidence
A review of the clinical trial evidence examining low-dose ketamine as an intervention for acute suicidal ideation. This article evaluates randomized controlled trials, naturalistic studies, and emergency department protocols demonstrating ketamine's rapid anti-suicidal effects.
Meta-Analyses of Low-Dose Ketamine for Treatment-Resistant Depression
A comprehensive review of major meta-analyses examining the efficacy and safety of low-dose ketamine in treatment-resistant depression. This overview synthesizes findings across multiple systematic reviews to characterize effect sizes, response rates, and durability of antidepressant outcomes.
Contact Low Dose Ketamine
Send corrections, provider questions, or advertising inquiries.